How the redox state regulates immunity

Article  (Accepted Version)

Mullen, Lisa, Mengozzi, Manuela, Hanschmann, Eva-Maria, Alberts, Ben and Ghezzi, Pietro (2019) How the redox state regulates immunity. Free Radical Biology and Medicine. ISSN 0891-5849

This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/89956/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
How the Redox State Regulates Immunity

Lisa Mullen, Manuela Mengozzi, Eva-Maria Hanschmann, Ben Alberts, Pietro Ghezzi

1 Brighton and Sussex Medical School, Falmer, Brighton, UK
2. Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Germany

Abstract

Oxidative stress is defined as an imbalance between the levels of reactive oxygen species (ROS) and antioxidant defences. The view of oxidative stress as a cause of cell damage has evolved over the past few decades to a much more nuanced view of the role of oxidative changes in cell physiology. This is no more evident than in the field of immunity, where oxidative changes are now known to regulate many aspects of the immune response, and inflammatory pathways in particular. Our understanding of redox regulation of immunity now encompasses not only increases in reactive oxygen and nitrogen species, but also changes in the activities of oxidoreductase enzymes. These enzymes are important regulators of immune pathways both via changes in their redox activity, but also via other more recently identified cytokine-like functions. The emerging picture of redox regulation of immune pathways is one of increasing complexity and while therapeutic targeting of the redox environment to treat inflammatory disease is a possibility, any such strategy is likely to be more nuanced than simply inhibiting ROS production.

1. Introduction

Inflammatory disease is often associated with oxidative changes. Some of the earliest reports in terms of the biochemical mechanisms involved were the identification of arachidonic acid oxidation products [1] and the inhibitory effects of antioxidants on the production of prostaglandins and thromboxanes [2]. These findings were based on even
earlier studies on rancidification of lipids in food and, were similarly measured by following the formation of malondialdehyde (MDA), also defined as thiobarbituric acid-reactive substance [3, 4].

A second aspect is that reactive oxygen species (ROS) produced by neutrophils during the oxidative burst to kill bacteria [5] can cause collateral damage and inflammation [6]. Pioneering studies by McCord have also implicated ROS in postischemic tissue injury [7], thus broadening the list of diseases for which oxidative stress is implicated. This prompted the hypothesis that low-molecular weight antioxidants [8], as well as antioxidant enzymes [9], could ameliorate inflammatory and immune-mediated disease.

With the discovery of inflammatory cytokines in the 1980s [10, 11] and the success of the cytokine theory of disease with the approval of anti-TNF antibodies for the treatment of rheumatoid arthritis and Crohn’s disease, it was only natural that researchers investigated the effect of antioxidants and oxidants on cytokine production. We reported that endogenous glutathione (GSH) is an inhibitor of TNF production [12], a study that was followed by others showing inhibitory effects of antioxidants on inflammatory cytokine production [13].

However, a molecular mechanism for this effect was clarified only in the early 1990s in the laboratory of Patrick Baueerle, with the finding that antioxidants inhibit, and ROS activate, the transcription factor NF-κB, which is involved in the transcription of many inflammatory genes, including cytokines [14, 15].

2. From the concept of oxidative stress to those of redox regulation and eustress

NF-κB was first described in 1986 as a transcription factor acting on immunoglobulin genes in B cells [16]. The first connection with inflammation was the discovery that TNF activates NF-κB [17]. Later, it was found that NF-κB activates the transcription of TNF [18] and other cytokines [19] in response to inflammatory stimuli. NF-κB entered the redox arena in 1991 with a paper from Baeuerle’s lab which showed for the first time that NF-κB is activated by H2O2 and its activation by inflammatory stimuli is inhibited by thiol containing compounds including N-acetylcysteine [14]. This paper has since been cited over 4100 times. This study
raised the important point that apparently ROS can function exclusively as second messengers only in a narrow range of concentrations, while at higher concentrations are mainly toxic [14].

3. Molecular mechanisms of redox regulation: the role of protein thiols

The seminal study by Schreck et al. [14] describing the effects of ROS on activation of NF-κB did not attempt to investigate the mechanism by which NF-κB is redox regulated; the mechanism by which NF-κB is redox regulated was simply depicted by an arrow with no further detail given. We will focus here on oxidoreduction of cysteine residues in proteins, in particular to form intramolecular disulfides or mixed disulfides with glutathione (protein glutathionylation).

In fact, while the classical explanation found in textbooks is that protein cysteines can exist in two forms, either as free thiols or engaged in a structural disulfide to hold together the 3D structure of the protein, there are many more forms of cysteine oxidation. Those that are reversible are clear candidates for redox regulatory mechanisms. The essence of this aspect of redox regulation is that these post-translational modifications can regulate protein activity. Figure 1 outlines two examples of cysteine oxidation: formation of intra-protein disulfide and glutathionylation, together with the similarities to the well-known regulatory mechanism of protein phosphorylation.
Figure 1. Regulation of protein function by cysteine oxidation. A) Formation of reversible intraprotein disulfides non-enzymatically or by direct oxidation with GSH or thiol-disulfide exchange with GSSG. The panel also depicts the oxidation of a thiol by the action of ROS (the figure depicts the formation of a sulfenic acid, but it could also be a sulfinic (–SO₂H) or sulfonic (–SO₃H) acid. B) Glutathionylation where mixed disulfides are formed between a cysteine residue in a protein and GSH. C) Alteration of protein activity by phosphorylation catalyzed by kinases or phosphatases.

Protein cysteines can also be S-nitrosylated by reactive nitrogen species or oxidized by ROS to form sulfenic, sulfinic or sulfonic acids. Oxidation to sulfinic and sulfenic acid is reversible [20] and may thus have regulatory roles. Enzymes of the family of the protein thiol-disulfide
oxidoreductase (PDOR), such as thioredoxin (Trx), glutaredoxin (Grx), Quescin-sulfhydryl oxidase (Qsox), or sulfiredoxin (Srx) can catalyze the oxidoreduction of protein thiols and disulfides in either direction, depending on the redox environment [21-23].

One of the first examples of a protein involved in inflammation that can be regulated by formation of an intramolecular disulfide is Keap-1 [24], resulting in activation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2; as discussed below). Among the first proteins reported to undergo glutathionylation was the p50 subunit of NF-κB, as well as others of pivotal importance in regulating the inflammatory response. The top half of Table 1 lists some examples of proteins relevant to inflammation that are subject to regulation by different forms of cysteine oxidation.

Table 1. Key redox regulated proteins in immunity

| Reversible disulfide formation |  |  |  |
| --- | --- | --- | --- |
| Modification | Target cysteine(s) | Example | Functions affected | Reference |
| Intra-protein disulfide | C257, C273, C288, C297 | Keap1 | Liberation and activation of Nrf2 | [24] |
| Inter-protein disulfide | C54, C347 | NEMO | Dimerization, IKK binding | [25] |
| S-glutathionylation | ? | p50 | DNA binding | [26] |
| S-glutathionylation | ? | STAT3 | DNA and Jak2 binding | [27] |
| S-glutathionylation | C91 | MAL | Interaction with Myd88 | [28] |

| Other reversible forms of oxidation |  |  |  |
| --- | --- | --- | --- |
| Modification | Example | Functions affected | Reference |
| Methionine oxidation | M358 | Alpha-1 antitrypsin | Inhibition | [29],[30] |
| S-nitrosylation | C15, C20 | Surfactant protein D | Activation of pro-inflammatory properties | [31] |
| S-cysteinylation | various | peptides | Affect MHC recognition | [32] |
Although this discussion of molecular mechanisms focuses on protein thiol-disulfides and glutathionylation, other forms of protein oxidation have been shown to regulate inflammation, the most important of which are listed in the lower half of Table 1. Methionine oxidation to methionine sulfoxide has long been known to inactivate alpha-1 proteinase inhibitor (alpha-1-antitrypsin) [29], as well as other proteins relevant in inflammation and immunity such as interferons and chemotactic peptides (reviewed in [33]). This oxidation is reversed by methionine sulfoxide reductase that reactivates the target protein [34].

It should be noted that most cysteines that are susceptible to glutathionylation can also undergo S-nitrosylation or cysteinylation as shown below:

**S-nitrosylation:** P-SH + XNO -> PSNO

**S-cysteinylation:** P-SH + Cys-SH -> P-s-s-Cys

There are examples of both of these post-translational oxidative changes in regulating immune function. S-nitrosylation targets many proteins in the immune system [35] such as surfactant proteins [31], innate immune receptors such as NLRP3 (Mishra et al., 2012; Mao et al., 2013) and signaling molecules such as MyD88 (Into et al., 2008) which is important in inflammatory signaling downstream of Toll-like receptors. Cysteinylation can occur during processing of peptide ligands for presentation on MHC molecules thereby affecting antigen processing and presentation to T cells [32].

Another aspect to be taken into account is that not all cysteines in a protein are equally susceptible to oxidative post-translational modifications. This is determined by several factors including the pK value of the cysteine, which is affected by the neighbouring aminoacids as well as its steric accessibility, particularly in the case of glutathionylation which requires reaction with GSH or GSSG (reviewed in [36]).
4. The immuno-regulatory roles of protein thiol-disulfide oxidoreductases

Protein thiol-disulfide oxidoreductases (PDORs) are enzymes that catalyze the oxidoreduction of protein thiols and disulfides as described above. There are a number of PDORs with different and some overlapping functions. Table 2 lists the main mammalian PDORs.

Table 2. Main mammalian protein thiol-disulfide oxidoreductases.

| Enzyme                                | Symbol | Main reaction catalyzed                                                                                                                                 |
|----------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Glutaredoxin (old name, thioltransferase) | Grx    | Mainly a reductant. Reduction of PSSG to PSH. Needs glutathione reductase and NADPH. PSSG -> PSH + GSH                                                                 |
| Thioredoxin                            | Trx, Txn | Mainly a reductant. Generic reduction of protein disulfides. Needs Trx reductase and NADPH. PSSP -> PSH                                                                 |
| Peroxiredoxin                          | Prdx   | Prdxs are thioredoxin peroxidases, and catalyze the reduction of H₂O₂ to water using reduced Trx as the electron donor. H₂O₂ + Trx-(SH)₂ -> H₂O + Trx-(SS) |
| Protein disulfide isomerase            | PDI    | Mainly an oxidant. Oxidation of protein thiols to form structural disulfides. PSH + GSSG -> PSS + GSH                                                                 |
| Sulfiredoxin                           | Srx    | Reductant. Reduces Prdx oxidized to sulfinic acid using ATP and a thiol as electron donor; also reduces glutathionylated proteins. PSOH + XSH + ATP -> PSH + XSSX + ADP |
| Quiescin-sulphydryl oxidase            | Qsox   | Oxidizes protein thiols to disulfides by concomitantly reducing O₂ to H₂O₂. PSH + O₂ -> PSS + H₂O₂                                                                 |

PSH, protein thiol; PSSP, protein disulfide; PSSG, protein-GSH mixed disulfide

5. Activities of extracellular protein thiol-disulfide oxidoreductases

There are many lines of evidence demonstrating the involvement of intracellular PDORs in the intracellular signaling pathways downstream of activated pattern recognition receptors on innate immune cells. One of the best examples of this are the Toll-like receptors (TLRs) that, upon recognition of PAMPs or DAMPs, initiate complex intracellular signaling cascades that culminate in activation of the transcription factors AP1 and NF-KB. Once activated, these transcription factors drive the expression of genes coding for cytokines and other pro-
inflammatory proteins. PDORs play important roles at various points in these signaling pathways as shown in Fig. 2 and reviewed in [37, 38]. It is important to note that the effects of the PDORs in these signaling pathways are reliant on their oxidoreductase activity and not simply due to non-enzymatic effects of these proteins. Thus, changes in the redox states of these enzymes can result in dissociation of molecules that, once released from their associations, can participate in downstream signaling to facilitate changes in gene expression. These redox changes can be viewed as another form of post-translational modification that regulates intracellular signaling in a similar manner to protein phosphorylation.
Fig. 2. Regulation of inflammatory signaling pathways by PDORs. Activation of cell-surface located TLRs by pathogen associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) triggers an intracellular signaling pathway that leads to transcription of cytokines, chemokines and other proteins involved in inflammatory responses. Activation of TLRs results in activation of mitogen-activated protein kinase kinase (MAPKK) and dissociation and degradation of inhibitor of kappa B (iKB) resulting in activation of the transcription factors AP-1 (activator protein -1) and NF-κB (shown here as the p65 and p50 subunits) respectively. The signaling pathway downstream of TLR activation is reliant on sequential phosphorylation of various signaling molecules (shown here by the P in the upper right of the protein name). The points in these signaling pathways that are regulated by PDORs are indicated by the names of the PDORs involved, together with the effect of each enzyme of the activity of the target signaling molecule. Nrx: nucleoredoxin is a Trx-related enzyme. Modified from [37] (CC BY 4.0). Additional abbreviations: activator protein 1 (AP-1); apoptosis signal-regulating kinase 1 (ASK1); c-Jun N-terminal kinase (JNK); damage-associated molecular patterns (DAMP); DD loop (DD); IκB kinase (IKK); interleukin-1 receptor-associated kinase (IRAK); myeloid
differentiation primary response 88 (MYD88); pathogen-associated molecular patterns (PAMP); redox factor-1 (Ref1); Toll-IL-1-receptor domain (TIR); tumor necrosis factor receptor-associated factor (TRAF).

Although PDORs are intracellular enzymes, some of them are secreted under various physiological conditions. However, PDORs may not be enzymatically active in the extracellular environment due to a lack of necessary cofactors (e.g. Trx requires Trx reductase and NADPH; Prdx requires Trx, Trx reductase and NADPH; Grx requires GSH) but have been reported to have cytokine-like activities. In some cases, these activities were described before identifying the hypothetical cytokine as a PDOR. These activities are listed in Table 3.

Table 3. Biological activities of secreted PDORs

| Enzyme | Alternative names | Extracellular actions | Reference |
|--------|-------------------|-----------------------|-----------|
| Trx    | Adult T-cell leukemia-derived factor (ADF) | T-cell proliferation and activation | [39, 40] |
| Trx    | Chemotactic factor (chemokine) | | [41] [42] |
| Trx    | Eosinophil cytotoxicity-enhancing factor (ECEF) | Increases antibody-dependent cytotoxicity of eosinophils | [43] |
| Prdx   | (NK) cell enhancing factor (NKEF) | NK cell activation | [44] |
| Prdx   | Induce inflammatory cytokines | | [45, 46] |
| PDI    | Thrombus formation; beta 2 integrin regulation | | [47] [48] |
| QSOX   | Regulates extracellular matrix adhesion | | [49] |

Probably the best such example is represented by Trx. This enzyme was discovered by Arne Holmgren as the intracellular enzyme serving as an essential cofactor of ribonucleotide reductase (reviewed in: [50]), and its sequence was determined in 1968 [51]. Years later, in 1985, the laboratory of virologist Junji Yodoi characterized a cytokine produced by adult T-cell leukemia cells that upregulates the expression of interleukin 2 receptor in T cells, and named it adult T-cell leukemia-derived factor (ADF) [39]. Once the protein was sequenced, four years later, it was found to be identical to Trx [52].
Since then, various other activities of extracellular Trx have been described, most notably as a chemotactic factor [42] and, in its truncated form (Trx80), as a monocyte activator [53, 54]. In addition, extracellular Trx released by antigen-presenting cells generates small-molecular weight thiols via its enzyme action that contribute to T cell activation [55].

Germane to this story, researchers purified a cytokine that stimulated eosinophil antibody-dependent cytotoxic function, and found that the purified protein was identical to Trx [43]. More recently, Prdxs have been reported to be secreted and act as pro-inflammatory agents [45, 56] possibly through activation of Toll-like receptors [57].

6. Redox regulation of signaling molecules

The pioneering studies on NF-κB mentioned above were the first demonstration of redox regulation of a specific protein in an inflammatory signaling pathway. As indicated in Table 1, several elements of the inflammatory signaling pathway are redox regulated via glutathionylation. Interestingly, earlier ideas of how oxidative stress mediates the induction or maintenance of inflammation, viewed glutathione mainly as an antioxidant and free radical scavenger that would inhibit inflammation (see for instance our earlier studies [12, 58]). However, within the concept of redox regulation glutathione can be seen as a signaling molecule, similar to ATP which is not only an energy-storage molecule but, through protein phosphorylation, is also essential in cellular signaling [59]s. We recently described how macrophages depleted of GSH do not show a full response to endotoxin in terms of activation of gene expression profile [60]. If GSH was acting mainly as an inhibitor of ROS-mediated activation of inflammatory pathways, we would expect its depletion to exacerbate the response to endotoxin. However, we found that there were more inflammation-induced genes that require GSH for full induction [60]. While GSH may participate in redox regulation in different ways, protein glutathionylation is one of the most studied mechanisms.

To obtain a list of the genes involved in innate immunity that were reported to undergo glutathionylation, we performed a literature search on August 9, 2019, searching for “glutathionylation or glutathionylated” and each of the 849 in the Gene Ontology term “innate immune response” (GO:0045087) and the 1326 in the Gene Ontology term “inflammatory response” (GO:0006954). The search returned 967 publications and abstracts.
were read to identify the proteins reported to undergo glutathionylation. Those not related in any way to inflammation or immunity were excluded. The final list of 41 genes were (by official gene symbol): ALOX5, CASP1, CASP8, CSTA, CYP4, DUSP1, ENOS, FAS, GAPDH, IKBKB, IL1B, IL1SRII, ITGA4, JAK1, JAK2, MAL/TIRAP, NCF1, NFKB, NLRP3, NOS3, P47PHOX, PFN1, PON1, PP2A, PRDX1, PRDX2, PTEN, RELA, S100A8, S100A9, SERPINA1, SIRT3, STAT1, STAT3, THOP1, TP53, TRAF3, TRAF6, TTR, TXN1, VIM. For many of these proteins, glutathionylation can affect their activity, as in the case of STAT3 (see Table 1). This indicates that redox regulation may occur at several steps in the immune signalling pathways.

We have analyzed the list of genes above using the reactome analysis tool [61, 62], to highlight specific innate immune signalling pathways susceptible to redox regulation. The results of this analysis are shown in Figure 3, which highlights the signalling pathways involved in the activation of inflammatory signalling where regulation by glutathionylation is involved. Several interleukin signalling pathways (left side of the figure) are overrepresented, as is neutrophil degranulation.
7. ROS and activation of the NLRP3 inflammasome

The nucleotide-binding oligomerization domain (NOD)-like receptor containing pyrin domain 3 (NLRP3) inflammasome that is necessary for intracellular processing of pro-IL-1β and secretion of active IL-1β [63]s was first described by Martinon et al [64]s. This was an important discovery as it led to greater understanding of how IL-1β, a pro-inflammatory cytokine heavily implicated in inflammatory diseases such as RA, gout and cardiovascular disease, is produced and secreted during innate immune responses. Since then, numerous studies have investigated the importance of ROS in NLRP3 activation. The potential role of
ROS in NLRP3 activation stemmed from early studies demonstrating that inhibition of NADPH oxidase enzymes by diphenyleneiodonium (DPI) reduced IL-1β secretion in alveolar macrophages or primary human monocytes [65-67]. This was confirmed by knock-down of NADPH oxidase p22phox subunits which resulted in inhibition of IL-1β secretion in response to monosodium urate (MSU) crystals or asbestos[66]. Together, these data strongly suggested that NADPH oxidase-induced ROS production was critical for activation of NLRP3. However, the necessity of ROS generated by NADPH oxidases for activation of NLRP3 has since been disputed by studies using mononuclear cells from patients with CGD, an immunodeficiency disease caused by defects in phagocyte NADPH oxidase subunits. MSU and silica induced IL-1β secretion in these cells was unaffected despite the loss of NADPH oxidase induced ROS [68-70]. Mitochondria[71-73] and xanthine oxidase[74, 75] have since emerged as important sources of ROS in activating NLRP3 but there are also several studies that contradict the hypothesis that ROS are necessary for NLRP3 activation and secretion of IL-1β[76, 77]. Therefore, the exact role of ROS in activating NLRP3 remains a matter of debate, with numerous studies showing conflicting results as summarized in Table 3. It is likely that, like any mechanistic hypothesis, this cannot be generalized and only applies to specific experimental models.

Thus, the current understanding of the role of ROS in NLRP3 activation is unclear and likely involves other strands of redox regulation rather than ROS levels in isolation. A number of elements of the redox regulatory machinery have been shown to be involved in activation of NLRP3 including the antioxidant enzyme SOD1[78], glutathionylation of caspase-1 via increased superoxide levels[79] and activation of Nrf2 resulting in transcription of glutathione, thioredoxin and other antioxidants such as NADPH dehydrogenase 1 and heme[80, 81]. This hypothesis posits that redox modulation, rather than simply ROS levels, is the important factor in IL-1β processing[82] and provides a possible explanation for the evidence both for and against the involvement of ROS in NLRP3 activation. Furthermore, a wide array of structurally diverse NLRP3 activators have been identified (in addition to MSU crystals), including viral RNA, components of microbial cell walls, nucleic acid, pore-forming toxins, silica, asbestos, ATP and serum amyloid A. The diversity of these molecules make it likely that NLRP3 is not activated by direct interaction with these stimuli, rather by a common cellular event such as dysregulation of cellular homeostasis[83].
| Cell type                      | Findings                                                                 | For / Against | Year, Reference |
|-------------------------------|---------------------------------------------------------------------------|---------------|-----------------|
| Alveolar macrophages          | Treatment of cells with ATP induces ROS. Inhibition of NADPH-oxidase derived ROS by DPI reduced ATP-induced caspase-1 activation and IL-1β production | For           | 2007 [65]       |
| THP-1 cells                   | Knockdown of p22phox subunit of NADPH-oxidase supressed IL-1β release in THP-1 cells in response to asbestos and MSU | For           | 2008 [66]       |
| THP-1 cells                   | Extracellular ATP causes NADPH-oxidase induced oxidation and IL-1β secretion in THP-1 cells. Treatment with NAC and DPI inhibited caspase-1 processing in response to extracellular ATP | For           | 2004 [67]       |
| THP-1 cells                   | Inhibition of mitochondrial complex I induced ROS production which correlated closely with NLRP3-dependant IL-1β secretion. Inhibition of mitochondrial respiration abrogated IL-1β production and caspase-1 activation | For           | 2011 [73]       |
| Alveolar macrophages          | Inhibition of mitochondrial ROS by SS-31 dose-dependently inhibited cyclic stretch induced caspase-1 activation and IL-1β production | For           | 2013 [72]       |
| Murine BMDMs                  | Mitochondrial dysfunction is linked to NLRP3 activation and mitochondrial DNA is required for NLRP3 inflammasome-mediated IL-1β secretion | For           | 2012 [84]       |
| HEK293T cells                 | Redox regulated TXNIP binds directly to NLRP3 in response to MSU exposure. siRNA blocking of TXNIP expression abrogated caspase-1 activation and IL-1β secretion | For           | 2010 [85]       |
| THP-1 cells                   | IL-1β secretion is ROS-dependant but in an NADPH-oxidase-independent manner. Cells from p22phox- and NOX2-deficient patients had normal IL-1β secretion | Both          | 2010 [69]       |
| Human PBMCs                   | IL-1β secretion is normal in mononuclear cells from patients with chronic granulomatous disease (CGD), a disease characterised by defective NADPH-oxidase enzymes | Against       | 2010 [68]       |
| Human monocytes               | NLRP3 can be activated in a ROS-independent manner in monocytes from patients with CGD. Inhibition of ROS with DPI did not decrease caspase-1 activation or secretion of IL-1β in cells from these patients | Against       | 2010 [70]       |
| Murine macrophages            | Elevated ROS in SOD1-deficient mouse macrophages inhibited caspase-1 activation. This could be reversed dose-dependently with SOD-mimetics which caused increased ATP-induced IL-1β secretion | Against       | 2008 [79]       |
| Murine BMDMs                  | Nrf2, a redox sensitive transcription factor for a range of antioxidant genes, is essential for inflammasome activation and IL-1β secretion in response to cholesterol | Against       | 2011 [80]       |
| Murine BMDMs                  | IL-1β secretion in TXNIP-deficient macrophages secreted normal levels of IL-1β compared to wild-type macrophages in response to MSU, ATP and islet amyloid polypeptide | Against       | 2010 [86]       |
| Murine macrophages            | Inhibition of ROS by DPI and NAC inhibited NLRP3 priming but not activation. Only had an effect when cells were preincubated with ROS inhibitors prior to activation | Against       | 2011 [87]       |

Source: [88].
8. Redox mechanisms that affect macrophage polarization in the context of chronic inflammation

Macrophages are extremely plastic cells that play a central role in inflammation and its resolution [89]. The ontogeny, the tissue-specific environment and altered homeostasis at the site of injury, including signals generated by TLR ligands, such as microbial products or danger-associated molecular patterns (DAMPs), are all involved in causing phenotypic and functional changes [90, 91]. Macrophages can be broadly classified into M1 and M2 subtypes [89, 91, 92]. M1 have microbiidal functions and are considered pro-inflammatory whereas M2 promote cell proliferation and contribute to wound healing. M1 respond to TLR agonists and to IFN-γ produced by Th1 cells by activating iNOS and producing NO and ROS to kill pathogens, and secrete pro-inflammatory cytokines, such as IL-8, TNF and IL-1β, and IL-12 that drives Th1 responses. M2 express high levels of arginase that hydrolyses arginine to ornithine, essential for collagen synthesis and cell proliferation, thus favouring tissue repair and regeneration; they generally produce TGF-β and IL-10 that sustain Th2 responses, and may have anti-inflammatory functions [93-95]. M1 and M2 macrophages are also characterised by different metabolism; M2 rely on mitochondrial oxidative phosphorylation for energy production, whereas M1 are preferentially glycolytic [96-98].

Although M1 and M2 macrophages represent the extremes of a spectrum of different functional subsets described in vitro and not necessarily present in vivo, it is accepted that an immune response broadly skewed towards M1 (and Th1) polarization may be involved in the pathogenesis of chronic inflammatory disease [89, 99], and greater knowledge of the mechanisms that differentiate M1 from M2 and drive M2 polarization might be exploited for therapeutic purposes.

All the different M1 and M2 functions are driven by a variety of transcription factors. M1 macrophages mainly express STAT1, NF-κB, IRF5 and AP-1, whereas STAT6, PPAR-γ and IRF4 are predominantly expressed in M2 [91]. HIF-1 is highly expressed in M1 and coordinates glycolytic metabolism and pro-inflammatory cytokine production whereas PPAR-γ in M2 mediates fatty acid oxidation and mitochondrial oxidative phosphorylation [96, 97, 100]. Interestingly, most of these transcription factors (e.g. HIF-1, NF-κB, STAT6, PPAR-γ) are
redox targets [14, 101-104]. Some specific redox mechanisms that regulate M1 and M2 polarization by affecting pro-inflammatory cytokine production, cell metabolism and/or transcription factor activation are described below.

ROS have been shown to increase pro-inflammatory cytokine production, and therefore M1 polarization, by potentiating LPS-induced MAPK activation [105, 106]; a mechanism might be inhibition of MAPK phosphatases, redox targets that can be inactivated by reversible (and irreversible) oxidation of their catalytic cysteine [107-109]). Also NF-kB can act as a redox switch to increase M1; in microglia oxidation of the NF-kB p50 subunit by H$_2$O$_2$ decreases its binding to DNA and increases pro-inflammatory cytokine production and M1/M2 balance [102], confirming the predominant inhibitory role of NF-kB p50 on M1 polarization [110]. In addition, extensive literature has linked ROS to activation of the inflammasome, required for production of mature IL-1$\beta$, highly expressed in M1 macrophages [65-67, 71-73]. However, as discussed above, investigation of the role of ROS on the activation of the inflammasome has produced controversial results (Table 4).

Many redox intracellular targets may be responsible for the impact of ROS on cell metabolism. Mitochondrial oxidative phosphorylation can be inhibited through S-glutathionylation, mediated by Grx2, of complex I of the mitochondrial respiratory chain [111]. In addition, ROS can increase glycolysis by augmenting HIF-1 stabilisation and glucose uptake. In this respect, HIF can be stabilised in normoxia following inactivation of prolyl hydroxylase domain enzymes (PHDs), responsible for targeting HIF-\(\alpha\) subunits to the proteasome; inhibition of their activity is due to oxidation of cysteines in the active site [101]. Glucose uptake can be increased by H$_2$O$_2$-induced phosphorylation of AMPK and Akt, mediating translocation of the main glucose transporter GLUT4 to the plasma membrane [112]. Inhibition of phosphatases by ROS, also mentioned above, might explain the increased phosphorylation of AMP and Akt [107, 108]. Decreased oxidative phosphorylation and increased glycolysis will result in increased M1 polarization.

All the above evidence points to the possibility that inhibiting ROS might inhibit M1 and induce M2 polarization. However, ROS are also required for induction of M2 polarization, as shown in human and murine macrophages and in vivo in mice [103, 113, 114]. Interestingly, in mice with pulmonary fibrosis H$_2$O$_2$ produced by SOD1 enhanced M2 polarization by
increasing the transcriptional activity of STAT6, due to redox regulation of a cysteine in its Src homology domain 2 [103].

The fact that ROS may play a role in resolution of inflammation is also supported by the observation that individuals with CGD, characterized by the lack of NOX2-mediated ROS production, in addition to increased infections exhibit also hyperinflammatory responses and an increased frequency of autoimmune disease [115, 116]. Also, polymorphisms affecting Ncf1, the p47 subunit of NOX2, resulting in lower production of ROS, are associated with many autoimmune chronic inflammatory disorders [117], suggesting that ROS might inhibit chronic inflammation. Transgenic rescue of Ncf1 in mononuclear phagocytes of Ncf1-mutant mice inhibited hyperinflammation, demonstrating that ROS produced by NOX2 in macrophages are required for resolution of inflammation [118]. In addition, it is interesting to note that Weyand et al reported in a series of studies that T cells from RA patients are ROS-deficient, due to a shift in metabolism; glycolysis is inhibited and glucose is diverted into the pentose phosphate pathway (PPP), resulting in production of lower levels of intracellular ROS and excessive NADPH [119-121]. This “reductive stress” correlates with an inflammatory phenotype and Th1/Th17 polarization, which can be reverted by treatment with oxidants [122].

Although there is evidence that ROS support M1 polarization and a pro-inflammatory response [97, 102, 104, 111], paradoxically ROS-deficiency can result in chronic inflammation. Thus, ROS also seem to favour M2 polarization and resolution of inflammation. A possible mechanism might be through induction of NRF2 [104]. In this regard, recent data have shown that NRF2 activation can enhance M2 polarization [123-126]. It could also be predicted that decreased physiological ROS levels might prevent feedback induction of NRF2, resulting in amplification of the M1 response.

There many studies that describe how changes in the redox extracellular and intracellular environment and redox modifications of transcription factors and signalling molecules can shape the immune response by driving functional changes in macrophages. However, contrasting evidence makes it difficult to reach firm conclusions and to identify redox therapeutic targets [90, 98, 104, 127].
9. Redox regulation in inflammatory disease

The association of inflammation with oxidative stress and vice versa has been recognized for decades and is perhaps unsurprising given the intimate links between aspects of innate immunity, for example the oxidative burst in neutrophils, and ROS levels. However, it has proved difficult to fully elucidate the exact relationship between increases in oxidative stress and inflammation and in particular to determine the extent to which this is a causal relationship. This is an important question because if there is a causal relationship between these conditions, it may be possible to reduce inflammation by alleviating oxidative stress. This may be of particular relevance to diseases where chronic inflammation causes tissue damage and eventual loss of function. There are certainly some diseases where increases in oxidative stress seem to contribute to the pathology, rather than being merely a consequence of increased levels of inflammation. Some of these conditions are discussed below with a focus on conditions where reducing oxidative stress has been demonstrated to ameliorate the symptoms of disease either in appropriate animal models or in humans.

9.1. Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease with a worldwide incidence of about 1%. Although RA is a systemic disease, it primarily affects synovial joints where chronic inflammatory processes can lead to progressive degradation of articular cartilage and eventual bone destruction. The exact causes of RA are unknown, but likely involve a combination of genetic susceptibility and environmental factors that result in a loss of immune tolerance[128]. T cells, B cells and over-production of pro-inflammatory cytokines play key roles in the pathogenesis of RA[129].

Many studies have indicated that increased levels of ROS occur in RA[130], both in synovial fluid [131] and in plasma[132]. However, increases in ROS are only significant if not adequately buffered by antioxidant defenses, in which case the result is oxidative stress and potential oxidative damage to biological molecules and cells. This is indeed the case in RA, where increased oxidative stress is a characteristic of the disease[133-135], and perhaps at least partially explained by the lower levels of antioxidants such as GSH, Vitamin C, thiols[136-138] and the antioxidant enzyme catalase[136] in these patients. Furthermore,
several studies have demonstrated oxidative damage in tissues and synovial fluid in RA, examples of which include lipoperoxidation products[139], oxidative damage of hyaluronic acid[140], oxidation of low-density lipoproteins[141] and protein oxidation[142]. Furthermore, synovial cells from RA patients show upregulation of the transcription factor Nrf2, which is known to be activated in response to oxidative stress and limits cartilage destruction in a mouse model of arthritis [143, 144].

A recent systematic review of the role of oxidative stress in RA concluded that oxidative stress is likely to be implicated in the pathogenesis of RA, and may even serve as a biomarker of disease, but that no firm conclusions could be made due to the heterogeneity of the data [145]. Such heterogeneity of results from a combination of a heterogeneous patient population and the inherent problems in accurately measuring biomarkers of oxidative stress.

An important question is whether oxidative stress and the concomitant oxidative damage is directly involved in initiating and/or maintaining disease. It is possible that the increases in oxidative stress occurring in RA are a result of the inflammatory response that is dysregulated and continually active in disease. However, an interesting finding from a prospective cohort study is that high levels of antioxidants in healthy individuals were protective against the development of RA[146] and at least some studies have reported a correlation between disease activity and oxidative stress in RA patients[147], although in other studies this relationship did not reach significance[148]. More recently, a strong correlation between ROS levels and concentrations of TNF and IL-6 were demonstrated in the serum of RA patients [149]. Therefore, the idea of using antioxidants for therapeutic purposes in RA is attractive.

Several studies have tested the hypothesis that antioxidant supplementation could be used to therapeutic benefit in RA. Most studies have used measurements of MDA and TAC as measures of oxidative stress and concentrations of TNF and/or IL-6 as measures of inflammation. Treatment of RA patients with antioxidants such as NAC[150], Vitamins A and/or E[151, 152] or CoQ10[153] did reduce the levels of MDA in the blood and in some, but not all, cases the levels of TAC. However, in those studies that measured disease activity using the DAS28 score, there was no significant change indicating that there was little effect of the antioxidant supplementation on clinical disease.
Animal models of RA have been used to good effect to elucidate the relationship between oxidative stress and the disease process. Arthritis in these models is certainly associated with increased oxidative stress, mirroring the human disease, with increases in iNOS and MDA and decreased Gpx and SOD activity in the affected joints [154]. Intriguingly, local overexpression of antioxidant enzymes (SOD3 or catalase) ameliorated arthritis in rats with antigen-induced arthritis [155] or mice with collagen-induced arthritis [156] suggesting that oxidative stress is directly involved in the pathogenesis of disease. The mechanisms involved are less easy to understand. The pro-inflammatory cytokines TNF and IL-6 are key mediators of inflammation in RA, but the concentrations of the cytokines were not affected by the increased SOD3 or catalase. The protective effects of the antioxidant enzymes were instead due to decreases in catabolic enzymes such as matrix metalloproteinases that are up-regulated in joints affected by arthritis. The decrease in clinical score was thus a result of decreased matrix and cartilage degradation rather than inhibiting inflammation [155]. It is also important to note that the most successful outcomes on disease activity in rodents were achieved by local overexpression of antioxidant enzymes via gene transfer, an approach not yet possible in humans. Local reduction of ROS and oxidative stress in the affected joints may be necessary for therapeutic effects in RA which would explain why the clinical trials described above where systemic administration of antioxidants had little effect on disease activity.

9.2. Gout

Gout is an inflammatory arthritis driven by the production of the pro-inflammatory cytokine, IL-1β. It has a worldwide prevalence of 0.1-10 % [157] and is characterized by episodes of acute inflammation generated in response to monosodium urate (MSU) deposits in synovial joints. Uric acid is the major antioxidant in the blood, contributing around 60% of the free radical scavenging capacity [158]. During periods of hyperuricemia, when the concentration of serum uric acid increases, crystals of uric acid form and are deposited in synovial joints. It is these crystals that are recognized by innate immune cells and result in activation of the NLRP3 inflammasome that processes pro-IL-1β for secretion. The inflammation associated with an acute gout attack is driven primarily by secreted IL-1β [159].
Interestingly, although the greatest risk factor for gout is hyperuricemia, itself an antioxidant, gout is associated with increased oxidative stress as indicated by higher MDA levels and lower SOD and catalase activities compared with healthy controls[160]. At a cellular level, MSU crystals induce the production of ROS in human synoviocytes [161] and monocytes [88]. This ability of MSU crystals to induce ROS production is significant as ROS have been postulated to be involved in activation of NLRP3 which is necessary for secretion of IL-1β. However, as discussed above, this relationship between ROS levels and activation of NLRP3 is still unclear.

The front-line treatment for gout attacks is allopurinol which inhibits the activity of the enzyme xanthine oxidase thereby preventing the production of uric acid from xanthine. Interestingly, allopurinol treatment also decreases oxidative stress in gout patients, possibly by reducing the production of ROS from the xanthine oxidase reaction[160]. However, it is difficult to fully elucidate the pathological importance of oxidative stress in gout. Allopurinol is therapeutic presumably by lowering uric acid levels and possibly by decreasing oxidative stress, but it is difficult to ascertain the relative contributions of these actions to the therapeutic benefit.

9.3. Multiple sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects approximately 2.5 million people worldwide. Disease is characterised by relapsing-remitting episodes following peripheral immune attack on the CNS. This causes inflammation in the grey and white matter of the CNS leading to destruction of myelin in the brain and spinal cord. Demyelination and persistent glial cell-mediated neuroinflammation within the CNS contributes to the accumulation of progressive neurodegeneration and disability[162].

A large and convincing body of literature exists on the importance of oxidative stress in MS pathophysiology. MS is particularly interesting in this regard because oxidative stress appears to be a fundamental and possibly causative element of disease as opposed to being a by-product of inflammation as may be the case in other diseases. There are multiple accounts of increased oxidative stress in MS patients, both in the CNS [163-166] and the periphery [167-]
Markers of oxidative damage in MS brain tissue include oxidative damage to cellular membrane lipids[166], generation of peroxynitrite which damages proteins and oxidative damage to nucleic acids by the formation of 8-hydroxy-2′-deoxyguanosine[171]. Furthermore, chronically-activated microglial cells produce reactive oxygen species (ROS) that can influence mitochondrial function and energy metabolism that can then result in autoimmune-independent neurodegeneration [172].

It is interesting that a number of antioxidant enzymes such as superoxide dismutase (SOD), catalase, haem-oxygenase [166] and peroxiredoxins 2[173] and 6[174] are upregulated in MS, probably as a result of chronic oxidative stress. Peroxiredoxin 6 not only protected against inflammation in a mouse model of MS, but also against disruption of the blood brain barrier by inhibiting the activity of MMP9[174], similar to the ability of catalase and SOD3 to reduce cartilage degradation in a mouse model of RA by inhibiting MMPs[155]. Indeed, antioxidant enzymes have been tested in animal models of experimental optic neuritis [175-177] or MS i.e. experimental autoimmune encephalomyelitis (EAE)[174, 178] for therapeutic effects and have been shown to ameliorate the symptoms of disease. Unsurprisingly, a combination of antioxidant enzymes (e.g. SOD and catalase) was more effective in reducing the clinical signs of EAE than either enzyme alone [177]. Notably, all of these effects of antioxidant enzymes that have been studied in vivo have relied on the generation of transgenic mice or overexpression of enzymes via gene therapy with adenoviral vectors or engineered syngeneic cells[155]. Although these approaches are very useful for proof-of-concept testing in animal models, they are not yet appropriate for treating human disease.

However, the importance of oxidative stress in MS and the potential therapeutic benefits of reducing this is underlined by the fact that one of the front-line treatments for MS, dimethyl fumarate (DMF) exerts therapeutic effects at least partially by reducing oxidative stress via activation of Nrf2[179, 180]. Furthermore, dietary intake of exogenous antioxidants such as flavonoids and α-lipoic acid reduce the clinical signs of disease in animal models of MS[181, 182] and there is now substantial interest in the use of oral antioxidants for improving the clinical symptoms of MS [183].
Conclusions

The studies summarized in this review clearly indicate that redox modifications are involved in the regulation of innate immunity and inflammation. This highlights the role of endogenous ROS and redox reactions in regulating immune processes, indicating that use of broad-spectrum ROS scavengers may affect important signaling pathways. It should be mentioned that, so far, no specific antioxidant molecule has been approved for clinical use in any of the inflammatory diseases mentioned in this review, and there were no relevant Cochrane reviews available at the time of writing. On the other hand, two Cochrane reviews on the use of antioxidants in two acute inflammatory conditions (acute respiratory distress syndrome and systemic inflammatory response syndrome) did not recommend their therapeutic use [184, 185]. Even the assumption that the pharmacological action of DMF in MS is mediated by activation of Nrf2 has been challenged by a study showing its effectiveness in a model of MS in Nfr2-knockout mice [186].

Nonetheless, there is strong evidence that oxidative stress may in fact occur in several inflammatory diseases and it is possible that it may represent a druggable target for at least some of them. However, in view of the literature discussed in this review, it is probable that decimating ROS levels with antioxidant scavengers may result in several non-specific effects, and current studies point to the necessity for more targeted strategies such as specific inhibition of ROS-producing enzymes involved in disease that would leave the other ROS-generating pathways intact [187, 188].
References

[1] M. Hamberg, B. Samuelsson, Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets, Proc. Natl. Acad. Sci. U. S. A. 71(9) (1974) 3400-4.
[2] A. Falanga, M.G. Doni, F. Delaini, G. De Bellis Vitti, L. Imberti, M.B. Donati, G. de Gaetano, Unbalanced plasma control of TxA2 and PGI2 synthesis in vitamin E-deficient rats, Am. J. Physiol. 245(5 Pt 1) (1983) H867-70.
[3] R.O. Sinnhuber, 2-Thiobarbituric acid method for the measurement of rancidity in fishery products. II. The quantitative determination of malonaldehyde, Food Technol. 12 (1958) 9-12.
[4] H. Takayama, M. Okuma, H. Uchino, A simple method for estimation of lipooxygenase and cyclooxygenase pathways in human platelets—the use of thiobarbituric acid reaction, Thromb. Haemost. 44(3) (1980) 111-4.
[5] B.D. Cheson, J.T. Curnette, B.M. Babior, The oxidative killing mechanisms of the neutrophil, Prog. Clin. Immunol. 3 (1977) 1-65.
[6] J.A. Smith, Neutrophils, host defense, and inflammation: a double-edged sword, J. Leukoc. Biol. 56(6) (1994) 672-86.
[7] J.M. McCord, Oxygen-derived free radicals in postischemic tissue injury, N. Engl. J. Med. 312(3) (1985) 159-63.
[8] U. Singh, S. Devaraj, I. Jialal, Vitamin E, oxidative stress, and inflammation, Annu. Rev. Nutr. 25 (2005) 151-74.
[9] J.M. McCord, Free radicals and inflammation: protection of synovial fluid by superoxide dismutase, Science 185(150) (1974) 529-31.
[10] B. Beutler, A. Cerami, Cachectin and tumour necrosis factor as two sides of the same biological coin, Nature 320(6063) (1986) 584-8.
[11] C.A. Dinarello, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood 117(14) (2011) 3720-32.
[12] P. Peristeris, B.D. Clark, S. Gatti, R. Faggioni, A. Mantovani, M. Mengozzi, S.F. Orencole, M. Sironi, P. Ghezzi, N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production, Cell. Immunol. 140(2) (1992) 390-9.
[13] P. Gosset, B. Wallaert, A.B. Tonnel, C. Fourneau, Thiol regulation of the production of TNF-alpha, IL-6 and IL-8 by human alveolar macrophages, Eur. Respir. J. 14(1) (1999) 98-105.
[14] R. Schreck, P. Rieber, P.A. Baeuerle, Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1, EMBO J. 10(8) (1991) 2247-58.
[15] P.A. Baeuerle, T. Henkel, Function and activation of NF-kappa B in the immune system, Annu. Rev. Immunol. 12 (1994) 141-79.
[16] R. Sen, D. Baltimore, Multiple nuclear factors interact with the immunoglobulin enhancer sequences, Cell 46(5) (1986) 705-16.
[17] E.J. Duh, W.J. Maury, T.M. Folks, A.S. Fauci, A.B. Rabson, Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat, Proc. Natl. Acad. Sci. U. S. A. 86(15) (1989) 5974-8.
[18] A.N. Shakhov, M.A. Collart, P. Vassalli, S.A. Nedospasov, C.V. Jongeneel, Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages, J. Exp. Med. 171(1) (1990) 35-47.
[19] E.M. Palsson-McDermott, L.A. O’Neill, Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4, Immunology 113(2) (2004) 153-62.
[20] S. Akter, L. Fu, Y. Jung, M.L. Conte, J.R. Lawson, W.T. Lowther, R. Sun, K. Liu, J. Yang, K.S. Carroll, Chemical proteomics reveals new targets of cysteine sulfinic acid reductase, Nat. Chem. Biol. 14(11) (2018) 995-1004.

[21] S. Lee, S.M. Kim, R.T. Lee, Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance, Antioxid Redox Signal 18(10) (2013) 1165-207.

[22] E. Pedone, D. Limauro, K. D’Ambrosio, G. De Simone, S. Bartolucci, Multiple catalytically active thioredoxin folds: a winning strategy for many functions, Cell. Mol. Life Sci. 67(22) (2010) 3797-814.

[23] H.J. Atkinson, P.C. Babbitt, An atlas of the thioredoxin fold class reveals the complexity of function-enabling adaptations, PLoS Comput. Biol. 5(10) (2009) e1000541.

[24] A.T. Dinkova-Kostova, W.D. Holtzclaw, R.N. Cole, K. Itoh, N. Wakabayashi, Y. Katoh, M. Yamamoto, P. Talalay, Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants, Proc. Natl. Acad. Sci. U. S. A. 99(18) (2002) 11908-13.

[25] S.M. Cote, T.D. Gilmore, R. Shaffer, U. Weber, R. Bollam, M.S. Golden, K. Glover, M. Herscovitch, T. Ennis, K.N. Allen, A. Whitty, Mutation of nonessential cysteines shows that the NF-kappaB essential modulator forms a constitutive noncovalent dimer that binds IkappaB kinase-beta with high affinity, Biochemistry 52(51) (2013) 9141-54.

[26] E. Pineda-Molina, P. Klatt, J. Vazquez, A. Marina, M. Garcia de Lacoba, D. Perez-Sala, S. Lamas, Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding, Biochemistry 40(47) (2001) 14134-42.

[27] Y. Xie, S. Kole, P. Precht, M.J. Pazin, M. Bernier, S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling, Endocrinology 150(3) (2009) 1122-31.

[28] M.M. Hughes, P. Lavrencic, R.C. Coll, T. Ve, D.G. Ryan, N.C. Williams, D. Menon, A. Mansell, P.G. Board, M. Mobli, B. Kobe, L.A.J. O’Neill, Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling, Proc. Natl. Acad. Sci. U. S. A. 114(32) (2017) E6480-E6489.

[29] D. Johnson, J. Travis, Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor, J. Biol. Chem. 253(20) (1978) 7142-4.

[30] A. Janoff, C. George-Nascimento, S. Rosenberg, A genetically engineered, mutant human alpha-1-proteinase inhibitor is more resistant than the normal inhibitor to oxidative inactivation by chemicals, enzymes, cells, and cigarette smoke, Am. Rev. Respir. Dis. 133(3) (1986) 353-6.

[31] E.N. Atochina-Vasserman, S-nitrosylation of surfactant protein D as a modulator of pulmonary inflammation, Biochim. Biophys. Acta 1820(6) (2012) 763-9.

[32] M.A. Haque, J.W. Hawes, J.S. Blum, Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition, J. Immunol. 166(7) (2001) 4543-51.

[33] R.L. Levine, J. Moskowitz, E.R. Stadtman, Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulation, JUBMB Life 50(4-5) (2000) 301-7.

[34] H. Carp, A. Janoff, W. Abrams, G. Weinbaum, R.T. Drew, H. Weissbach, N. Brot, Human methionine sulfoxide-peptide reductase, an enzyme capable of reactivating oxidized alpha-1-proteinase inhibitor in vitro, Am. Rev. Respir. Dis. 127(3) (1983) 301-5.

[35] M. Ibanez-Vea, H. Huang, X. Martinez de Morentin, E. Perez, M. Gato, M. Zuazo, H. Arasanz, J. Fernandez-Irigoyen, E. Santamaría, G. Fernandez-Hinojal, M.R. Larsen, D. Escors, G. Kochan, Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography, J. Proteome Res. 17(3) (2018) 1172-1182.

[36] P. Ghezzi, P. Di Simplicio, Glutathionylation pathways in drug response, Curr. Opin. Pharmacol. 7(4) (2007) 398-403.

[37] I. Lorenzen, L. Mullen, S. Bekeschus, E.M. Hanschmann, Redox Regulation of Inflammatory Processes Is Enzymatically Controlled, Oxid. Med. Cell. Longev. 2017 (2017) 8459402.

[38] K. Dominko, D. Dikic, Glutathionylation: a regulatory role of glutathione in physiological processes, Arh. Hig. Rada Toksikol. 69(1) (2018) 1-24.
K. Teshigawara, M. Maeda, K. Nishino, T. Nikaido, T. Uchiyama, M. Tsudo, Y. Wano, J. Yodoi, Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression, J. Mol. Cell. Immunol. 2(1) (1985) 17-26.

J. Yodoi, M. Maeda, Discovery of ATL: an odyssey in retrospect, Int. J. Hematol. 94(5) (2011) 423-8.

K. Hori, M. Hirashima, M. Ueno, M. Matsuda, S. Waga, S. Tsurufuji, J. Yodoi, Regulation of eosinophil migration by adult T cell leukemia-derived factor, J. Immunol. 151(10) (1993) 5624-30.

R. Bertini, O.M. Howard, H.F. Dong, J.J. Oppenheim, C. Bizzarri, R. Sergi, G. Caselli, S. Pagliei, B. Romines, J.A. Wilshire, M. Mengozzi, H. Nakamura, J. Yodoi, K. Pekkari, R. Gurunath, A. Holmgren, L.A. Herzenberg, P. Ghezzi, Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells, J. Exp. Med. 189(11) (1999) 1783-9.

M.K. Balcewicz-Sablinska, E.E. Wollman, R. Gorti, D.S. Silberstein, Human eosinophil cytotoxicity-enhancing factor. II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor, J. Immunol. 147(7) (1991) 2170-4.

H. Shau, L.H. Butterfield, R. Chiu, A. Kim, Cloning and sequence analysis of candidate human natural killer-enhancing factor genes, Immunogenetics 40(2) (1994) 129-34.

T. Shichita, E. Hasegawa, A. Kimura, R. Sakaguchi, I. Takada, T. Sekiya, H. Ooboshi, T. Kitazono, T. Yanagawa, T. Ishii, H. Takahashi, S. Mori, M. Nishibori, K. Kuroda, S. Akira, K. Miyake, A. Yoshimura, Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain, Nat. Med. 18(6) (2012) 911-7.

L. Mullen, E.M. Hanschmann, C.H. Lillig, A. Holmgren, Physiological functions of thioredoxin and thioredoxin reductase, Eur. J. Biochem. 267(20) (2000) 6102-9.

A. Holmgren, Thioredoxin. 6. The amino acid sequence of the protein from escherichia coli B, Eur. J. Biochem. 6(4) (1968) 475-84.

Y. Tagaya, Y. Maeda, A. Mitsui, N. Kondo, H. Matsui, J. Hamuro, N. Brown, K. Arai, T. Yokota, H. Wakasugi, et al., ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of diethyl-reduction in the IL-2 receptor induction, EMBO J. 8(3) (1989) 757-64.

K. Pekkari, J. Avila-Carino, A. Bengtsson, R. Gurunath, A. Scheynius, A. Holmgren, Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes, Blood 97(10) (2001) 3184-90.

X. Cortes-Bratti, E. Basseres, F. Herrera-Rodriguez, S. Botero-Kleiven, G. Coppotelli, J.B. Andersen, M.G. Masucci, A. Holmgren, E. Chaves-Olarite, T. Frisan, J. Avila-Carino, Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogens, PLoS One 6(2) (2011) e16960.

G. Angelini, S. Gardella, M. Ardy, M.R. Ciriolo, G. Filomeni, G. Di Trapani, F. Clarke, R. Sitia, A. Rubartelli, Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation, Proc. Natl. Acad. Sci. U. S. A. 99(3) (2002) 1491-6.

S. Salzano, P. Checoni, E.M. Hanschmann, C.H. Lillig, L.D. Bowler, P. Chan, D. Vaudry, M. Mengozzi, L. Coppo, S. Sacre, K.R. Atkuri, B. Sahaf, L.A. Herzenberg, L.A. Herzenberg, L. Mullen, P.
Ghezzi, Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal, Proc. Natl. Acad. Sci. U. S. A. 111(33) (2014) 12157–12162.

[57] J.R. Riddell, X.Y. Wang, H. Minderman, S.O. Gollnick, Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4, J. Immunol. 184(2) (2010) 1022-30.

[58] P. Villa, P. Ghezzi, Effect of N-acetyl-L-cysteine on sepsis in mice, Eur. J. Pharmacol. 292(3-4) (1995) 341-4.

[59] J.D. Graves, E.G. Krebs, Protein phosphorylation and signal transduction, Pharmacol. Ther. 82(2-3) (1999) 111-21.

[60] M. Diotallevi, P. Checconi, A.T. Palamara, I. Celestino, L. Coppo, A. Holmgren, K. Abbas, F. Peyrot, M. Mengozzi, P. Ghezzi, Glutathione Fine-Tunes the Innate Immune Response toward Antiviral Pathways in a Macrophage Cell Line Independently of Its Antioxidant Properties, Front. Immunol. 8 (2017) 1239.

[61] A. Fabregat, S. Jupe, L. Matthews, K. Sidiropoulos, M. Gillespie, P. Garapati, R. Haw, B. Jassal, F. Korninger, B. May, M. Milacic, C.D. Roca, K. Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, G. Viteri, J. Weiser, G. Wu, L. Stein, H. Hermjakob, P. D’Eustachio, The Reactome Pathway Knowledgebase, Nucleic Acids Res. 46(D1) (2018) D649-D655.

[62] A. Fabregat, K. Sidiropoulos, G. Viteri, O. Forner, P. Marin-Garcia, V. Arnau, P. D’Eustachio, L. Stein, H. Hermjakob, Reactome pathway analysis: a high-performance in-memory approach, BMC Bioinformatics 18(1) (2017) 142.

[63] J. Tschopp, K. Schroder, NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?, Nat. Rev. Immunol. 10(3) (2010) 210-5.

[64] F. Martinon, K. Burns, J. Tschopp, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, Mol. Cell 10(2) (2002) 417-26.

[65] C.M. Cruz, A. Rinna, H.J. Forman, A.L. Ventura, P.M. Persechini, D.M. Ojcius, ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages, J. Biol. Chem. 282(5) (2007) 2871-9.

[66] C. Dostert, V. Petrilli, R. Van Bruggen, C. Steele, B.T. Mossman, J. Tschopp, Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica, Science 320(5876) (2008) 674-7.

[67] J. Hewinson, S.F. Moore, C. Glover, A.G. Watts, A.B. MacKenzie, A key role for redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human monocytes, J Immunol 180(12) (2008) 8410-20.

[68] F. Meissner, R.A. Seger, D. Moshous, A. Fischer, J. Reichenbach, A. Zychlinsky, Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease, Blood 116(9) (2010) 1570-3.

[69] R. van Bruggen, M.Y. Koker, M. Jansen, M. van Houdt, D. Roos, T.W. Kuiper, T.K. van den Berg, Human NLRP3 inflammasome activation is Nox1-4 independent, Blood 115(26) (2010) 5398-400.

[70] F.L. van de Veerdonk, S.P. Smeekens, L.A. Joosten, B.J. Kullberg, C.A. Dinarello, J.W. van der Meer, M.G. Netea, Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease, Proc Natl Acad Sci U S A 107(7) (2010) 3030-3.

[71] C.Y. Chen, C.H. Yang, Y.F. Tsai, C.C. Liaw, W.Y. Chang, T.L. Hwang, Ugonin U stimulates NLRP3 inflammasome activation and enhances NLRP3 inflammasome-mediated pathogen clearance, Redox Biol 11 (2017) 263-274.

[72] J. Wu, Z. Yan, D.E. Schwartz, J. Yu, A.B. Malik, G. Hu, Activation of NLRP3 inflammasome in alveolar macrophages contributes to mechanical stretch-induced lung inflammation and injury, J Immunol 190(7) (2013) 3590-9.

[73] R. Zhou, A.S. Yazdi, P. Menu, J. Tschopp, A role for mitochondria in NLRP3 inflammasome activation, Nature 469(7329) (2011) 221-5.
[74] A. Ives, J. Nomura, F. Martinon, T. Roger, D. LeRoy, J.N. Miner, G. Simon, N. Busso, A. So, Xanthine oxidoreductase regulates macrophage IL1beta secretion upon NLRP3 inflammasome activation, Nat Commun 6 (2015) 6555.

[75] S.A. Nicholas, V.V. Bubnov, I.M. Yasinska, V.V. Sumbayev, Involvement of xanthine oxidase and hypoxia-inducible factor 1 in Toll-like receptor 7/8-mediated activation of caspase 1 and interleukin-1beta, Cell Mol Life Sci 68(1) (2011) 151-8.

[76] S.S. Iyer, Q. He, J.R. Janczy, E.I. Elliott, Z. Zhong, S.C. Eisenbarth, S.L. Cassel, F.S. Sutterwala, Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation, Immunity 39(2) (2013) 311-323.

[77] R. Munoz-Planillo, P. Kuffa, G. Martinez-Colon, B.L. Smith, T.M. Rajendiran, G. Nunez, K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter, Immunity 38(6) (2013) 1142-53.

[78] N. Deigendesch, A. Zychlinsky, F. Meissner, Copper Regulates the Canonical NLRP3 Inflammasome, J Immunol 200(5) (2018) 1607-1617.

[79] F. Meissner, K. Molawi, A. Zychlinsky, Superoxide dismutase 1 regulates caspase-1 and endotoxic shock, Nat. Immunol. 9(8) (2008) 866-72.

[80] S. Freigang, F. Ampenberger, G. Spohn, S. Heer, A.T. Shamshiev, J. Kiesielow, M. Hersberger, M. Yamamoto, M.F. Bachmann, M. Kopf, Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis, Eur J Immunol 41(7) (2011) 2040-51.

[81] J.J. Jhang, Y.T. Cheng, C.Y. Ho, G.C. Yen, Monosodium urate crystals trigger Nrf2- and heme oxygenase-1-dependent inflammation in THP-1 cells, Cell Mol Immunol 12(4) (2015) 424-34.

[82] S. Tassi, S. Carta, R. Vene, L. Delfino, M.R. Ciriolo, A. Rubartelli, Pathogen-induced interleukin-1beta processing and secretion is regulated by a biphasic redox response, J Immunol 183(2) (2009) 1456-62.

[83] A. Liston, S.L. Masters, Homeostasis-altering molecular processes as mechanisms of inflammasome activation, Nat Rev Immunol 17(3) (2017) 208-214.

[84] K. Shimada, T.R. Crother, J. Karlin, J. Dagvadorj, N. Chiba, S. Chen, V.K. Ramanujan, A.J. Wolf, L. Vargas, D.M. Underhill, M. Vargas, C. Guerrero, Y. Wang, K.A. Fitzgerald, D.M. Underhill, T. Town, M. Arditi, Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis, Immunity 36(3) (2012) 401-14.

[85] R. Zhou, A. Tardivel, B. Thorens, I. Choi, J. Tschopp, Thioredoxin-interacting protein links oxidative stress to inflammasome activation, Nat Immunol 11(2) (2010) 136-40.

[86] S.L. Masters, A. Dunne, S.L. Subramanian, R.L. Hull, G.M. Tannahill, F.A. Sharp, C. Becker, L. Franchi, E. Yoshihara, Z. Chen, N. Mullooly, L.A. Mielke, J. Harris, R.C. Coll, K.H. Mills, K.H. Mok, P. Newsholme, G. Nunez, J. Yodoi, S.E. Kahn, E.C. Lavelle, L.A. O'Neill, Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes, Nat Immunol 11(10) (2010) 897-904.

[87] F. Bauernfeind, E. Bartok, A. Rieger, L. Franchi, G. Nunez, V. Hornung, Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome, J Immunol 187(2) (2011) 613-7.

[88] B. Alberts, Effects of oxidative stress on expression and activation of the NLRP3 inflammasome in primary human monocytes, Brighton and Sussex Medical School, 2019.

[89] A. Shapouri-Moghaddam, S. Mohammadian, H. Vazini, M. Taghadosi, S.A. Esmaeili, F. Mardani, B. Seifi, A. Mohammad, J.T. Afshari, A. Sahebkar, Macrophage plasticity, polarization, and function in health and disease, J Cell Physiol 233(9) (2018) 6425-6440.

[90] A. Weigert, A. von Knethen, D. Fuhrmann, N. Dehne, B. Brune, Redox-signals and macrophage biology, Mol Aspects Med 63 (2018) 70-87.

[91] S. Arora, K. Dev, B. Agarwal, P. Das, M.A. Syed, Macrophages: their role, activation and polarization in pulmonary diseases, Immunobiology 223(4-5) (2018) 383-396.

[92] C.D. Mills, K. Kincaid, J.M. Alt, M.J. Heilman, A.M. Hill, M-1/M-2 macrophages and the Th1/Th2 paradigm, Journal of immunology (Baltimore, Md.: : 1950) 164(12) (2000) 6166-73.
C.D. Mills, Anatomy of a discovery: m1 and m2 macrophages, Front Immunol 6 (2015) 212.

M. Rath, I. Muller, P. Kropf, E.I. Closs, M. Munder, Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginase Pathways in Macrophages, Front Immunol 5 (2014) 532.

A. Sica, A. Mantovani, Macrophage plasticity and polarization: in vivo veritas, J Clin Invest 122(3) (2012) 787-95.

G.M. Tannahill, A.M. Curtis, J. Adamik, E.M. Palsson-McDermott, A.F. McGettrick, G. Goel, C. Frezza, N.J. Bernard, B. Kelly, N.H. Foley, L. Zheng, A. Gardet, Z. Tong, S.S. Jany, S.C. Corr, M. Haneklaus, B.E. Caffrey, K. Pierce, S. Walmsley, F.C. Beasley, E. Cummins, V. Nizet, M. Whyte, C.T. Taylor, H. Lin, S.L. Masters, E. Gottlieb, V.P. Kelly, C. Clish, P.E. Auron, R.J. Xavier, L.A. O'Neill, Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha, Nature 496(7444) (2013) 238-42.

E.L. Mills, L.A. O'Neill, Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal, Eur J Immunol 46(1) (2016) 13-21.

H.R. Griffiths, D. Gao, C. Pararasa, Redox regulation in metabolic programming and inflammation, Redox Biology 12 (2017) 50-57.

E. Siouti, E. Andreakos, The many facets of macrophages in rheumatoid arthritis, Biochem Pharmacol 165 (2019) 152-169.

S.A. Eming, T.A. Wynn, P. Martin, Inflammation and metabolism in tissue repair and regeneration, Science 356(6342) (2017) 1026-1030.

G. Lee, H.S. Won, Y.M. Lee, J.W. Choi, T.I. Oh, J.H. Jang, D.K. Choi, B.O. Lim, Y.J. Kim, J.W. Park, P. Puigserver, J.H. Lim, Oxidative Dimerization of PHD2 is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1alpha Activation, Sci Rep 6 (2016) 18928.

T. Taetzsch, S. Levesque, C. McGraw, S. Brookins, R. Luqa, M.G. Bonini, R.P. Mason, U. Oh, M.L. Block, Redox regulation of NF-kappaB p50 and M1 polarization in microglia, Glia 63(3) (2015) 423-40.

C. He, A.J. Ryan, S. Murthy, A.B. Carter, Accelerated development of pulmonary fibrosis via Cu,Zn-superoxide dismutase-induced alternative activation of macrophages, J Biol Chem 288(28) (2013) 20745-57.

B. Brune, N. Dehne, N. Grossmann, M. Jung, D. Namgaladze, T. Schmid, A. von Knethen, A. Weigert, Redox control of inflammation in macrophages, Antioxid Redox Signal 19(6) (2013) 595-637.

A.C. Bulua, A. Simon, R. Maddipati, M. Pelletier, H. Park, K.Y. Kim, M.N. Sack, D.L. Kastner, R.M. Siegel, Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS), The Journal of experimental medicine 208(3) (2011) 519-33.

G.S. Youn, K.W. Lee, S.Y. Choi, J. Park, Overexpression of HDAC6 induces pro-inflammatory responses by regulating ROS-MAPK-NF-kappaB/AP-1 signaling pathways in macrophages, Free radical biology & medicine 97 (2016) 14-23.

H. Kamata, S. Honda, S. Maeda, L. Chang, H. Hirata, M. Karin, Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases, Cell 120(5) (2005) 649-61.

J. den Hertog, J. den Hertog, Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress, The EMBO journal 21(4) (2002) 493-503.

T.C. Meng, T. Fukada, N.K. Tonks, Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo, Mol Cell 9(2) (2002) 387-99.

C. Porta, M. Rimoldi, G. Raes, L. Brys, P. Ghezzi, D. Di Liberto, F. Dieli, S. Ghisletti, G. Natoli, P. De Baetselier, A. Mantovani, A. Sica, Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB, Proc Natl Acad Sci U S A 106(35) (2009) 14978-83.

R.J. Mailloux, W.G. Willmore, S-glutathionylation reactions in mitochondrial function and disease, Front Cell Dev Biol 2 (2014) 68.
Oxidative stress induces GLUT4 translocation by activation of PI3-K/Akt and dual AMPK kinase in cardiac myocytes, J Cell Physiol 215(3) (2008) 733-42.

ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages, Cell Res 23(7) (2013) 898-914.

Transcription factors STAT6 and KLF4 implement macrophage polarization via the dual catalytic powers of MCP1P, Journal of immunology (Baltimore, Md. : 1950) 194(12) (2015) 6011-23.

Hyperinflammation of chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase, Semin Immunopathol 30(3) (2008) 255-71.

Nuclear factor kappa-B (NFκB) regulates the expression of inflammatory cytokines and adhesion molecules in the macrophages, J Immunol 177(6) (2006) 3860-6.

Antioxidant enzymes play a critical role in regulating inflammation and oxidative stress in vivo, Arch Biochem Biophys 546 (2014) 83-8.

The Reactive Oxygen Species in Macrophage Polarization: Reflecting Its Dual Role in Progression and Treatment of Human Diseases, Oxidative Med. Cell. Longev. (2016) 16.
[130] S. Mateen, S. Moin, A.Q. Khan, A. Zafar, N. Fatima, Increased Reactive Oxygen Species Formation and Oxidative Stress in Rheumatoid Arthritis, Plos One 11(4) (2016) 15.
[131] P. Biemond, A.J. Swaak, J.F. Koster, Protective factors against oxygen free radicals and hydrogen peroxide in rheumatoid arthritis synovial fluid, Arthritis Rheum 27(7) (1984) 760-5.
[132] H.S. Ozturk, M.Y. Cimen, O.B. Cimen, M. Kacmaz, I. Durak, Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis, Rheumatol Int 19(1-2) (1999) 35-7.
[133] A. Garcia-Gonzalez, R. Gaxiola-Robles, T. Zenteno-Savin, Oxidative stress in patients with rheumatoid arthritis, Rev Invest Clin 67(1) (2015) 46-53.
[134] P. Vasanthi, G. Nalini, G. Rajasekhar, Status of oxidative stress in rheumatoid arthritis, Int. J. Rheum. Dis. 12(1) (2009) 29-33.
[135] M. Veselinovic, N. Barudzic, M. Vuletic, V. Zivkovic, A. Tomic-Lucic, D. Djuric, V. Jakovljevic, Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity, Mol. Cell. Biochem. 391(1-2) (2014) 225-232.
[136] A. Camli, O. Taspinar, T. Aydin, M. Kepekci, O.F. Ozer, Y. Keskin, S. Selek, A.S. Mutluer, RELATIONSHIP BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND MYELOPEROXIDASE AND CATALASE ACTIVITIES AND THIOL LEVELS, Oxid. Commun. 39(4) (2016) 3050-3057.
[137] S. Jaswal, H.C. Mehta, A.K. Sood, J. Kaur, Antioxidant status in rheumatoid arthritis and role of antioxidant therapy, Clinica chimica acta; international journal of clinical chemistry 338(1-2) (2003) 123-129.
[138] A. Tuzcu, R.A. Baykara, A. Omma, G.K. Acet, E. Dogan, M.C. Cure, S.C. Sandikci, E. Cure, S. Neselioğlu, O. Erel, Thiol/Disulfide homeostasis in patients with rheumatoid arthritis, Rom. J. Intern. Med. 57(1) (2019) 30-36.
[139] S. Taysi, F. Polat, M. Gul, R.A. Sari, E. Bakan, Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis, Rheumatol Int 21(5) (2002) 200-4.
[140] M. Grootveld, E.B. Henderson, A. Farrell, D.R. Blake, H.G. Parkes, P. Haycock, Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by proton-n.m.r. spectroscopy, Biochem J 273(Pt 2) (1991) 459-67.
[141] L. Dai, D.J. Lamb, D.S. Leake, M.L. Kus, H.W. Jones, C.J. Morris, P.G. Winyard, Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients, Free Radic Res 32(6) (2000) 479-86.
[142] I. Dalle-Donne, D. Giustarini, R. Rossi, R. Colombo, A. Milzani, Reversible S-glutathionylation of Cys 374 regulates actin filament formation by inducing structural changes in the actin molecule, Free Radic. Biol. Med. 34(1) (2003) 23-32.
[143] N. Maicas, M.L. Ferrandiz, R. Brines, L. Ibanez, A. Cuadrado, M.I. Koenders, W.B. van den Berg, M.J. Alcaraz, Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease, Antioxid Redox Signal 15(4) (2011) 889-901.
[144] C.I. Wruck, A. Fragoulis, A. Gurzynski, L.O. Brandenburg, Y.W. Kan, K.M. Chan, J. Hassenpflug, S. Freitag-Wolf, D. Varoga, S. Lippross, T. Pufe, Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice, Ann. Rheum. Dis. 70(5) (2011) 844-850.
[145] C.M. Quinonez-Flores, S.A. Gonzalez-Chavez, D.D. Najera, C. Pacheco-Tena, Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review, Biomed Res. Int. (2016) 14.
[146] J.R. Cerhan, K.G. Saag, L.A. Merlino, T.R. Mikuls, L.A. Criswell, Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women, Am J Epidemiol 157(4) (2003) 345-54.
[147] T. Jikimoto, Y. Nishikubo, M. Koshiba, S. Kanagawa, S. Morinobu, A. Morinobu, R. Saura, K. Mizuno, S. Kondo, S. Toyokuni, H. Nakamura, J. Yodoi, S. Kumagai, Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis, Mol Immunol 38(10) (2002) 765-72.
[148] O. Altindag, M. Karakoc, A. Kocyigit, H. Celik, N. Soran, Increased DNA damage and oxidative stress in patients with rheumatoid arthritis, Clin Biochem 40(3-4) (2007) 167-71.
[149] S. Mateen, S. Moin, S. Shahzad, A.Q. Khan, Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species, PLoS One 12(6) (2017) e0178879.

[150] M. Batooei, A. Tahamoli-Roudsari, Z. Basiri, F. Yasrebifar, M. Shahdoust, A. Eshraghi, M. Mehrpooya, S. Ataei, Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: a Randomized, Double Blind Clinical Trial, Reviews on recent clinical trials 13(2) (2018) 132-138.

[151] M. Jalili, S. Kolahi, S.R. Aref-Hosseini, M.E. Mamegani, A. Hekmatdoost, Beneficial role of antioxidants on clinical outcomes and erythrocyte antioxidant parameters in rheumatoid arthritis patients, International journal of preventive medicine 5(7) (2014) 835-840.

[152] I. Nourmohammadi, S. Athar-Nikazm, M.R. Vafa, A. Bidari, S. Jazayeri, A. Hoshyarrad, F. Hoseini, M. Fashi-Radmandi, Effects of antioxidant supplementations on oxidative stress in rheumatoid arthritis patients, Journal of biological sciences 10(1) (2010) 63-66.

[153] H. Abdollahzad, M.A. Aghdashi, M. Asghari Jafarabadi, B. Alipour, Effects of Coenzyme Q10 Supplementation on Inflammatory Cytokines (TNF-α, IL-6) and Oxidative Stress in Rheumatoid Arthritis Patients: a Randomized Controlled Trial, Archives of medical research 46(7) (2015) 527-533.

[154] R. Xu, Z. Liu, J. Hou, T. Huang, M. Yang, Osthole improves collagen-induced arthritis in a rat model through inhibiting inflammation and cellular stress, Cell Mol Biol Lett 23 (2018) 19.

[155] L. Dai, A. Claxson, S.L. Marklund, R. Feakins, N. Yousaf, Y. Chernajovsky, P.G. Winyard, Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes, Gene Ther 10(7) (2003) 550-8.

[156] T. Kelkka, J.P. Laurila, O. Sareila, P. Olofsson, M.O. Laukkonen, R. Holmdahl, Superoxide dismutase 3 limits collagen-induced arthritis in the absence of phagocyte oxidative burst, Mediators Inflamm 2012 (2012) 730469.

[157] C.F. Kuo, M.J. Grainge, W. Zhang, M. Doherty, Global epidemiology of gout: prevalence, incidence and risk factors, Nat Rev Rheumatol 11(11) (2015) 649-62.

[158] B.N. Ames, R. Cathcart, E. Schwiers, P. Hochstein, Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis, Proc. Natl. Acad. Sci. U. S. A. 78(11) (1981) 6858-62.

[159] C.A. Dinarello, How interleukin-1beta induces gouty arthritis, Arthritis Rheum 62(11) (2010) 3140-4.

[160] C.R. Acharya, A.K. Sharma, N.D. Kantharia, Involvement of oxidative stress in patients of gout and antioxidant effect of allopurinol, Int J Med Sci Public Health 4 (2015) 168-172.

[161] Y. Zamudio-Cuevas, K. Martinez-Flores, J. Fernandez-Torres, Y.A. Loissell-Baltazar, D. Medina-Luna, A. Lopez-Macay, J. Camacho-Galindo, C. Hernandez-Diaz, M.G. Santamaria- Olmedo, E.O. Lopez-Villegas, F. Oliviero, A. Scarn, J.F. Cerna-Cortes, M. Guitierrez, C. Pineda, A. Lopez-Reyes, Monosodium urate crystals induce oxidative stress in human synoviocytes, Arthritis Res. Ther. 18 (2016) 9.

[162] W.J. Huang, W.W. Chen, X. Zhang, Multiple sclerosis: Pathology, diagnosis and treatments, Exp Ther Med 13(6) (2017) 3163-3166.

[163] I.Y. Choi, P. Lee, P. Adany, A.J. Hughes, S. Belliston, D.R. Denney, S.G. Lynch, In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis, Mult. Scler. J. 24(8) (2018) 1029-1038.

[164] E. Gray, K. Kemp, K. Hares, J. Redondo, C. Rice, N. Scolding, A. Wilkins, Increased microglial catalase activity in multiple sclerosis grey matter, Brain Res. 1559 (2014) 55-64.

[165] H. Langemann, A. Kabiersch, J. Newcombe, Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis, Eur Neurol 32(5) (1992) 248-52.
[166] J. van Horssen, G. Schreibelt, J. Drexhage, T. Hazes, C.D. Dijkstra, P. van der Valk, H.E. de Vries, Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression, Free Radic Biol Med 45(12) (2008) 1729-37.

[167] A. Fiorini, T. Koudriavtseva, E. Bucaj, R. Coccia, C. Foppoli, A. Giorgi, M.E. Schinina, F. Di Domenico, F. De Marco, M. Perluigi, Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis, PLoS One 8(6) (2013) e65184.

[168] M. Karlik, P. Valkovic, V. Hancinova, L. Krizova, L. Tothova, P. Celc, Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis, Clin Biochem 48(1-2) (2015) 24-8.

[169] E. Miller, A. Walczak, J. Saluk, M.B. Ponczek, I. Majsterek, Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis, Clin Biochem 45(1-2) (2012) 26-30.

[170] S.R. Oliveira, A.P. Kallaur, E.M.V. Reiche, D.R. Kaimen-Maciei, C. Panis, M.A.B. Lozovoy, H.K. Morimoto, M. Maes, I. Dichi, A.N.C. Simao, Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis, Mol. Neurobiol. 54(4) (2017) 2961-2968.

[171] J. van Horssen, M.E. Witte, G. Schreibelt, H.E. de Vries, Radical changes in multiple sclerosis pathogenesis, Biochim Biophys Acta 1812(2) (2011) 141-50.

[172] J. Park, H. Choi, J.S. Min, S.J. Park, J.H. Kim, H.J. Park, B. Kim, J.I. Chae, M. Yim, D.S. Lee, Mitochondrial dynamics modulate the expression of pro-inflammatory mediators in microglial cells, J Neurochem 127(2) (2013) 221-32.

[173] D. Voigt, U. Scheidt, T. Derfuss, W. Bruck, A. Junker, Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation, Int. J. Mol. Sci. 18(4) (2017) 10.

[174] H.M. Yun, K.R. Park, E.C. Kim, J.T. Hong, PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption, Oncotarget 6(25) (2015) 20875-20884.

[175] J. Guy, E.A. Ellis, G.M. Hope, N.A. Rao, Influence of antioxidant enzymes in reduction of optic disc edema in experimental optic neuritis, J Free Radic Biol Med 2(5-6) (1986) 349-57.

[176] J. Guy, E.A. Ellis, G.M. Hope, N.A. Rao, Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental optic neuritis, Arch Ophthalmol 107(9) (1989) 1359-63.

[177] X. Qi, W.W. Hauswirth, J. Guy, Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis, Mol Vis 13 (2007) 1-11.

[178] J. Guy, X. Qi, W.W. Hauswirth, Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis, Proc Natl Acad Sci U S A 95(23) (1998) 13847-52.

[179] A. Hammer, A. Waschbisch, K. Kuhbandner, A. Bayas, D.H. Lee, A. Duschka, A. Haghikia, R. Gold, R.A. Linker, The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis, Ann Clin Transl Neurol 5(6) (2018) 668-676.

[180] A. Suneetha, K. Raja Rajeswari, Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review, J Chromatogr B Analyt Technol Biomed Life Sci 1019 (2016) 15-20.

[181] P. Chaudhary, G.H. Marracci, D.N. Bourdette, Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis, J Neuroimmunol 175(1-2) (2006) 87-96.

[182] J.J. Hendriks, J. Alblas, S.M. van der Pol, E.A. van Tol, C.D. Dijkstra, H.E. de Vries, Flavonoids influence monocyctic GTPase activity and are protective in experimental allergic encephalitis, J Exp Med 200(12) (2004) 1667-72.

[183] C. Waslo, D. Bourdette, N. Gray, K. Wright, R. Spain, Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis, Curr Treat Options Neurol 21(6) (2019) 26.

[184] A. Dushianthan, R. Cusack, V.A. Burgess, M.P. Grocott, P.C. Calder, Immunonutrition for acute respiratory distress syndrome (ARDS) in adults, Cochrane Database Syst Rev 1 (2019) CD012041.

[185] T. Szakmany, B. Hauser, P. Radermacher, N-acetylcysteine for sepsis and systemic inflammatory response in adults, Cochrane Database Syst Rev (9) (2012) CD006616.
[186] U. Schulze-Topphoff, M. Varrin-Doyer, K. Pekarek, C.M. Spencer, A. Shetty, S.A. Sagan, B.A. Cree, R.A. Sobel, B.T. Wipke, L. Steinman, R.H. Scannevin, S.S. Zamvil, Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2, Proc. Natl. Acad. Sci. U. S. A. 113(17) (2016) 4777-82.

[187] A.I. Casas, A.A. Hassan, S.J. Larsen, V. Gomez-Rangel, M. Elbatreek, P.W.M. Kleikers, E. Guney, J. Egea, M.G. Lopez, J. Baumbach, H. Schmidt, From single drug targets to synergistic network pharmacology in ischemic stroke, Proc. Natl. Acad. Sci. U. S. A. 116(14) (2019) 7129-7136.

[188] A.I. Casas, P.W. Kleikers, E. Geuss, F. Langhauser, T. Adler, D.H. Busch, V. Gailus-Durner, M.H. de Angelis, J. Egea, M.G. Lopez, C. Kleinschnitz, H.H. Schmidt, Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke, J. Clin. Invest. 130 (2019) 1772-1778.